Missouri to receive $15 million from national Depakote drug settlement

Wednesday, May 9, 2012 | 7:56 a.m. CDT; updated 9:08 a.m. CDT, Wednesday, May 9, 2012

JEFFERSON CITY — Missouri will get more than $15 million from a national settlement with Abbott Laboratories involving the marketing of the drug Depakote.

Depakote is an anti-seizure and mood-stabilizing drug prescribed for bipolar disorder. The company has admitted marketing the drug for unapproved uses, including treatment of schizophrenia, agitated dementia and autism.

Missouri Attorney General Chris Koster said the improper marketing resulted in false claims to the Medicaid program.

Abbott settled claims from dozens of states this week for more than $1.5 billion.


Like what you see here? Become a member.

Show Me the Errors (What's this?)

Report corrections or additions here. Leave comments below here.

You must be logged in to participate in the Show Me the Errors contest.


Danny Haszard May 9, 2012 | 9:25 a.m.

Reg-Abbott labs off-label promotion of Depakote.
I took Depakote for 6 years was ineffective for my condition PTSD,the doctor kept telling me to take it.
The saga of the schizophrenia drugs is one of incredible profit.Eli Lilly made $65 BILLION on Zyprexa franchise. Described as *the most successful drug in the history of neuroscience*.There is a whole underclass block of our society,including children in foster care that are the market for these drugs,but have little voice of protest if harmed by them.
--Daniel Haszard

(Report Comment)

Leave a comment

Speak up and join the conversation! Make sure to follow the guidelines outlined below and register with our site. You must be logged in to comment. (Our full comment policy is here.)

  • Don't use obscene, profane or vulgar language.
  • Don't use language that makes personal attacks on fellow commenters or discriminates based on race, religion, gender or ethnicity.
  • Use your real first and last name when registering on the website. It will be published with every comment. (Read why we ask for that here.)
  • Don’t solicit or promote businesses.

We are not able to monitor every comment that comes through. If you see something objectionable, please click the "Report comment" link.

You must be logged in to comment.

Forget your password?

Don't have an account? Register here.